3D Medicines (1244) H1 2024 earnings summary

Executive summary

• H1 revenue fell 41.4% YoY to RMB206.4m amid intense PD-1/PD-L1 competition; total comprehensive loss narrowed 40.0% to RMB114.1m.

• Envafolimab remained the sole commercialized product; the 12-candidate pipeline included seven clinical-stage candidates and four preclinical candidates.

Financial highlights

• Gross profit fell 41.9% to RMB188.9m; gross margin was 91.5% versus 92.3% in H1 2023.

• R&D expense declined 43.7% to RMB85.3m and selling and marketing expense declined 50.2% to RMB110.1m; administrative expense fell RMB34.9m to RMB43.5m.

• Adjusted total comprehensive loss widened to RMB97.7m from RMB81.5m; the calculation excludes preferred-share fair-value losses and share-based payment expenses.

• Basic and diluted loss per share was RMB0.42 versus RMB0.79; operating cash outflow was RMB179.7m versus RMB168.1m.

Outlook and guidance

• Plans to expand Envafolimab indications globally and pursue commercialization after MRCT completion and regulatory approvals.

• Management expects pipeline launches over the next 3–5 years, with oncology immunotherapy and cancer vaccines as development priorities.

• Management expects sales growth over the next five years, supported by expanded indications, improved sales strategies, partner capabilities and the subcutaneous formulation.

• Late-stage assets are expected to advance toward NDA and commercialization, with potential to contribute incremental operating cash flow.